Original ArticleCinacalcet hydrochloride treatment significantly improves all-cause and cardiovascular survival in a large cohort of hemodialysis patients
KEYWORDS
Cited by (0)
This study was partially supported by a research contract with Amgen. The contract provides for the authors to have final determination of the manuscript content, and the authors had sole responsibility for all data collection, analysis, reporting, and publication. GAB, MP, and SB are employed by Denver Nephrology; GS consults for Denver Nephrology. DZ, KN, and JL are employed by the Chronic Disease Research Group; WLStP is employed by the University of Minnesota and affiliated with the Chronic Disease Research Group. The Chronic Disease Research Group receives research funding from Amgen, and has received funding from Abbott. GAB, a consultant and advisor for Amgen and Genzyme, has received grant funding and speaking fees from Genzyme and has received grant funding from Shire. WLStP has received honoraria from Abbott and has served on its Advisory Board. The findings and discussion do not represent the USRDS or the National Institutes of Health.